FDA approves Pfizer vaccine on Monday

The US Food and Drug Administration (FDA) is expected to give full approval to the Pfizer-BioNTech vaccine on Monday, according to the New York Times.

As of Friday, regulators have been working to complete approval procedures and are in talks with the company, according to the report. The deadline seems to be Monday, but the possibility of extending the announcements by the FDA is open.

Pfizer was the first to receive an emergency license since December.

This approval is considered extremely important as it is expected to pave the way for vaccinations to public and private organizations that were waiting for the final approval to implement the obligation.

U.S. federal and state health officials hope an approved vaccine will catch the interest of Americans who were reluctant to make a drug that has been approved for emergency use.

After the "green light", universities and hospitals are expected to impose vaccination. The Pentagon said earlier this month that it planned to make vaccinations mandatory for the country's 1,3 million active troops "no later than" by the middle of next month.

Once approved, Pfizer-BioNTech plans to ask the FDA to approve the third dose of its vaccine.

The Moderna vaccine will be tested for full approval, which is expected several weeks later.

Last week, the US Food and Drug Administration (FDA) gave the green light to give a third dose of the Pfizer and Moderna vaccine to vulnerable groups.

It is noted that about 3% of American adults have an immune deficiency, but they represent, according to data from the CDC, 44% of patients treated for Covid, despite the fact that they have been fully vaccinated.

The United States has so far received emergency licenses and is administering the Moderna, Pfizer / BioNTech (two-dose) and Johnson & Johnson (single-dose) vaccines.

Some other countries, notably Israel, Germany and Chile, have already started or are planning to start giving a third dose of vaccine to the most vulnerable groups of the population as the more contagious Delta variant of the new coronavirus raises the risk of a recurrence of the health crisis. .

These countries defy the World Health Organization's call for a moratorium on third-dose doses until at least the end of September so that larger quantities of vaccines can be distributed to countries where the immunization campaign has not progressed.

The scientific community, meanwhile, remains divided over the value of the booster, or booster, third dose of COVID-19 in those who do not have comorbidities or are immunosuppressed.

His cases in the US have recently returned to the highest level in the last six months, which is attributed to the Delta variant.

Source: Iefimerida.gr